We develop scalable and optimized routes of synthesis
At MOEHS we constantly strive to develop synthetic industrial routesfor new Active Ingredients under criteria of commercial, industrial and intellectual property viability.
Our commercial department is at your disposal to update any details about the status
of our new developments.
At MOEHS we constantly strive to develop industrial synthesis routes for new Active Ingredients under criteria of commercial viability, industrial and intellectual property. Our sales department is at your disposal to update any details about the status of our new developments.
New Products - Developing now
| Product Name | CAS N° | Therapeutic Category | Additional Information | DMF / TP |
|---|---|---|---|---|
| ABROCITINIB (**) | 1622902-68-4 | Atopic Dermatitis | Laboratory batches | TP |
| DARIDOREXANT (**) | 1792993-84-0 | Insomnia | Laboratory batches | |
| ELAGOLIX (**) | 832720-36-2 | Uterine Fibroids, Endometriosis pain | Validation batches | TP |
| FEZOLINETANT(**) | 1629229-37-3 | Menopausal Vasomotor symptoms | Laboratory batches | |
| LASMIDITAN SUCCINATE | 439239-92-6 | Antimigraine | Kilo - Lab batches | DMF |
| LEMBOREXANT (**) | 1369764-02-2 | Insomnia treatment | Laboratory batches | TP |
| LINZAGOLIX(**) | 935283-04-8 | Uterine Fibroids. Endometriosis | Laboratory batches | |
| MAVACAMTEN (**) | 1642288-47-8 | Hypertrophic Cardiomyopathy | Kilo-lab batches | DMF |
| RELUGOLIX (**) | 737789-87-6 | Advanced prostate cancer. Uterine Fibroids, endometriosis | Kilo-lab batches | DMF |
| TAPINAROF (**) | 115781-08-3 | Psoriasis | Laboratory batches | |
| TIRBANIBULIN (**) | 897016-82-9 | Actinic Keratosis | Kilo - Lab batches | DMF |
| ZAVEGEPANT (**) | 1414976-20-7 | Acute migraine | laboratory batches | |
| VERICIGUAT (**) | 1350653-20-1 | Heart Failure | Kilo - lab batches | DMF |
New Products under testing
| Product Name | CAS N° | Brand Name | Therapeutic Category | Galenic Form |
|---|---|---|---|---|
| MAVACAMTEN (**) | 1642288-47-8 | Cardiovascular | capsules | |
| VERICIGUAT (**) | 1350653-20-1 | Antihypertensive | tablets |
(**) Moehs is working on this compound with experimental aims, exclusively directed to obtain market authorizations of our customers’ generic medicines. We don’t intend to make any activity against any valid patent protection, as well as we will not take charge of third party actions made with the provided compound and without our knowledge against this protection.
